Amgen v. Sandoz: Denosumab Biosimilar Case Ends in Consent Injunction
Amgen and Amgen Manufacturing Limited filed suit against Sandoz and four Novartis-affiliated entities in New Jersey over 21 patents covering their denosumab biologic. The case resolved after 374 days with Sandoz stipulating to validity and infringement of the Boyle ‘736 Patent and accepting an injunction barring U.S. sales of Jubbonti and Wyost through February 19, 2025.
Amgen secures consent injunction blocking Sandoz denosumab biosimilars
On May 1, 2023, Amgen, Inc. and Amgen Manufacturing Limited filed a patent infringement action in the District of New Jersey against Sandoz, Inc. and four related Novartis entities — Novartis Pharmaceuticals Production D.O.O., Sandoz GmbH, Lek Pharmaceuticals d.d., and Novartis AG. The complaint asserted 21 U.S. patents covering various aspects of denosumab, the active ingredient in Amgen’s blockbuster biologics Prolia and Xgeva, in response to Sandoz’s launch preparations for biosimilar products branded Jubbonti and Wyost.
The case closed on May 9, 2024 under a consent order and injunction entered on the basis of a Binding Term Sheet dated April 29, 2024. Sandoz stipulated that the asserted claims of U.S. Patent No. 7,364,736 — the Boyle ‘736 Patent — are valid, enforceable, and infringed by Jubbonti and Wyost. The resulting injunction bars Sandoz and its affiliates from making, using, selling, or importing those products in the United States until February 19, 2025. All remaining claims and counterclaims were dismissed with prejudice.
Resolution in 374 days, before any trial or claim construction ruling, suggests the parties reached a commercial accommodation rather than litigating through the full BPCIA pathway. The Binding Term Sheet and a subsequent long-form agreement govern the permitted scope of Sandoz’s activities, though those commercial terms are not public. The injunction’s fixed expiry — February 19, 2025 — implies a negotiated launch date was agreed privately, a common feature of biosimilar settlements that leaves market-entry timing off the public record.
Filing to Injunction Granted in 374 days
374 days — resolved before trial, consistent with BPCIA settlement timelines
Consent injunction and validity stipulation: what the order means for both parties
Consent injunction on stipulated validity and infringement
Rather than proceeding to trial, the parties entered a Binding Term Sheet under which Sandoz stipulated that the Boyle ‘736 Patent is valid, enforceable, and infringed. The court then entered a consent order translating that stipulation into a formal injunction. This mechanism allows the patent holder to obtain court-enforceable relief while giving the challenger certainty about its permitted commercial window — without a contested merits ruling.
Settled on stipulated termsAmgen secures injunction and validity admission on key denosumab patent
Amgen obtained a court order blocking U.S. sales of Jubbonti and Wyost through February 19, 2025, and a formal stipulation that the ‘736 Patent is valid and infringed. That stipulation, entered with prejudice, strengthens Amgen’s enforcement posture against other would-be denosumab biosimilar entrants, as it constitutes a judicial record of validity. The long-form settlement agreement likely includes a licensed or agreed entry date that protects Amgen’s exclusivity window.
Injunction + validity record securedSandoz accepts injunction but preserves post-expiry launch path
Sandoz’s stipulation to infringement and validity of the ‘736 Patent is a significant concession, but the fixed injunction expiry of February 19, 2025 suggests Sandoz negotiated a defined commercial entry point. The order expressly carves out that the stipulations do not apply to ‘Different Product Claims’ or ‘Non-Territory Claims,’ preserving Sandoz’s freedom to challenge other patents in other contexts. Remaining claims were dismissed with prejudice, closing off further litigation on the asserted patent set in this action.
Defined entry date; scope preservedBiosimilar sector: negotiated entry timelines dominate denosumab landscape
The Amgen–Sandoz resolution is consistent with a broader pattern in which BPCIA-pathway biosimilar entrants settle before trial, trading validity concessions for certainty on launch timing. With 21 patents asserted, any full trial would have been protracted and costly. The court-entered injunction — as opposed to a purely private settlement — gives Amgen an enforcement mechanism without the litigation risk of a contested validity ruling. Other denosumab biosimilar developers should note the ‘736 Patent’s court-endorsed validity.
BPCIA settlement pattern confirmedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Amgen, Inc. | Company | Biopharmaceutical company — holder of US7364736B2 and 20 further denosumab patentsSearch in Eureka ↗ |
| Co-Plaintiff | Amgen Manufacturing Limited | Individual | Search in Eureka ↗ |
| Defendant | Sandoz, Inc. | Company | Sandoz, Inc. and Novartis-affiliated generics entities seeking U.S. denosumab biosimilar launchSearch in Eureka ↗ |
| Co-Defendant | Novartis Pharmaceuticals Production D.O.O. | Individual | Search in Eureka ↗ |
| Co-Defendant | Sandoz, GmbH | Company | Search in Eureka ↗ |
| Co-Defendant | Lek Pharmaceuticals d.d. | Individual | Search in Eureka ↗ |
| Co-Defendant | Novartis, AG | Company | Search in Eureka ↗ |
| Plaintiff counsel | Jessica K. Formichella | Attorney | Counsel for Amgen, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Liza M. Walsh | Attorney | Counsel for Amgen, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Marc D. Haefner | Attorney | Counsel for Amgen, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Walsh Pizzi O’Reilly Falanga LLP | Law Firm | Representing Amgen, Inc.Search in Eureka ↗ |
| Defendant counsel | Edward T. Kole | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Eric I. Abraham | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Stephanie-Rose Orlando | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | William Murtha | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant law firm | Hill Wallack, LLP | Law Firm | Representing Sandoz, Inc.Search in Eureka ↗ |
| Defendant law firm | WILENTZ, GOLDMAN & SPITZER, PA | Law Firm | Representing Sandoz, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent order is notable for what Sandoz agreed to on the record: a stipulation that the Boyle ‘736 Patent is ‘valid, enforceable and infringed’ — language that carries judicial weight even though no contested merits determination was made. Crucially, the order limits the scope of that stipulation to the Sandoz biosimilar products and the Sandoz Denosumab Litigation only, expressly excluding preclusive effect on Different Product Claims or Non-Territory Claims. This carve-out suggests careful negotiation to preserve Sandoz’s optionality outside the specific product set and geography adjudicated here.
US7364736B2 — Boyle ‘736 Patent: denosumab antibody composition
U.S. Patent No. 7,364,736 — the Boyle ‘736 Patent — covers denosumab antibody compositions targeting RANKL (receptor activator of nuclear factor kappa-B ligand), the biological mechanism underlying bone resorption. Filed under application US10/180648, the patent sits at the core of Amgen’s denosumab intellectual property estate. Denosumab is the active ingredient in Prolia (osteoporosis) and Xgeva (bone metastases prevention), two high-revenue biologics. The ‘736 Patent’s composition-of-matter or antibody claims — if broad — represent the strongest form of exclusivity available in the biologic space.
With Sandoz stipulating to validity and infringement on the record, the ‘736 Patent now has an unusually strong enforcement posture for a biologic patent that has never been adjudicated on the merits. Twenty additional patents were asserted in this action, spanning what appears to be manufacturing, formulation, and process domains — a layered assertion strategy typical of originator biologics companies defending high-value franchises. Any developer pursuing a denosumab biosimilar in the U.S. must treat this patent as a primary clearance priority given the court-entered validity record.
Should your team run an FTO against US7364736B2 and the Amgen denosumab estate?
Any biopharmaceutical company, contract development and manufacturing organisation, or biosimilar developer working on RANKL-targeting antibodies or denosumab biosimilars should treat this case as a trigger for a full FTO review. The court-entered stipulation of validity and infringement on the ‘736 Patent — combined with 20 additional asserted patents — means the risk surface is materially larger than a single composition claim. Manufacturing process patents in the asserted set may also implicate CDMOs even where the final product is licensed.
PatSnap Eureka’s FTO Search Agent can map the full Amgen denosumab patent portfolio across composition, formulation, manufacturing, and process claims, identify which patents have surviving claims post-any IPR proceedings, and surface the claim language most relevant to your specific biosimilar construct. Eureka can also generate a landscape view of expiry dates across all 21 asserted patents to model your entry window against each layer of protection.
Run a freedom-to-operate analysis on US9359435B2 to assess your product’s exposure
Run FTO in Eureka →Related BPCIA denosumab and anti-RANKL biosimilar patent litigation
Cases involving BPCIA biosimilar patent disputes over denosumab and anti-RANKL antibodies in U.S. district courts, including consent injunctions and multi-patent assertions.
What this case signals for the biosimilar and BPCIA IP landscape
A 21-patent assertion resolved by consent injunction reveals how originator biologics companies manage biosimilar entry through structured settlements.
Validity stipulations in consent orders create precedent pressure on follow-on biosimilar filers
When a biosimilar developer stipulates to validity and infringement in a court order, that record can be cited in subsequent actions against other biosimilar entrants. Companies with pending or approved denosumab ANDAs should assess the ‘736 Patent’s enforceability in light of this order before launch planning advances.
Fixed injunction expiry dates signal privately negotiated launch windows
The February 19, 2025 injunction expiry was not a court determination — it reflects a commercial date agreed in the Binding Term Sheet. Monitoring injunction expiry dates in BPCIA settlements is a reliable proxy for negotiated biosimilar launch timelines when the underlying license terms are confidential.
Amgen v Sandoz — key questions answered
Sandoz stipulated that the asserted claims of U.S. Patent No. 7,364,736 (the Boyle ‘736 Patent) are valid, enforceable, and infringed by making, using, selling, or importing Jubbonti and Wyost in the United States. This stipulation was entered as part of a consent order and injunction based on a Binding Term Sheet dated April 29, 2024. The stipulation expressly does not apply to Different Product Claims or Non-Territory Claims as defined in the Binding Term Sheet.
The consent injunction entered in Case No. 1:23-cv-02406 expires on February 19, 2025. This fixed expiry date was negotiated by the parties and reflected in the Binding Term Sheet. It signals a privately agreed commercial launch window for Sandoz, though the specific terms governing any licensed or permitted sales after that date are contained in a confidential long-form settlement agreement.
Amgen asserted 21 U.S. patents in Case No. 1:23-cv-02406. The only patent subject to a validity and infringement determination in the consent order is U.S. Patent No. 7,364,736 (the Boyle ‘736 Patent). The remaining claims and counterclaims relating to the other 20 patents were dismissed with prejudice as part of the settlement.
U.S. Patent No. 7,364,736 covers denosumab antibody compositions targeting RANKL, a key mechanism in bone resorption. It is the only patent in this case to receive a court-entered validity and infringement determination, even though the determination was by stipulation rather than contested adjudication. This gives the ‘736 Patent a judicially endorsed validity record, which is relevant to enforcement against other denosumab biosimilar developers. Composition patents of this type typically represent the strongest exclusivity layer in a biologic portfolio.
The defendants were Sandoz, Inc. (the U.S. entity), Sandoz GmbH, Novartis Pharmaceuticals Production D.O.O., Lek Pharmaceuticals d.d., and Novartis AG. All are affiliated with the Novartis group, of which Sandoz is the generics and biosimilars division. The multi-entity structure is consistent with BPCIA litigation practice, where plaintiffs name the full corporate chain involved in manufacturing, importing, and commercialising the biosimilar product to ensure complete injunctive relief.
PatSnap Eureka searches patents and litigation data to answer instantly.